AUPP977899A0 - Improvement of t cell mediated immunity - Google Patents

Improvement of t cell mediated immunity

Info

Publication number
AUPP977899A0
AUPP977899A0 AUPP9778A AUPP977899A AUPP977899A0 AU PP977899 A0 AUPP977899 A0 AU PP977899A0 AU PP9778 A AUPP9778 A AU PP9778A AU PP977899 A AUPP977899 A AU PP977899A AU PP977899 A0 AUPP977899 A0 AU PP977899A0
Authority
AU
Australia
Prior art keywords
improvement
cell mediated
mediated immunity
immunity
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AUPP9778A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Monash University
Original Assignee
Monash University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monash University filed Critical Monash University
Priority to AUPP9778A priority Critical patent/AUPP977899A0/en
Publication of AUPP977899A0 publication Critical patent/AUPP977899A0/en
Priority to PCT/AU2000/000329 priority patent/WO2000062657A2/en
Priority to NZ514975A priority patent/NZ514975A/en
Priority to BR0009712-8A priority patent/BR0009712A/en
Priority to KR1020017013148A priority patent/KR20020007371A/en
Priority to EP00916705A priority patent/EP1191975A4/en
Priority to JP2000611797A priority patent/JP2002542174A/en
Priority to AU37977/00A priority patent/AU779067B2/en
Priority to CA002370296A priority patent/CA2370296A1/en
Priority to CNB008089663A priority patent/CN100376288C/en
Priority to US09/966,575 priority patent/US20020071829A1/en
Priority to US09/966,576 priority patent/US20020071833A1/en
Priority to US09/965,394 priority patent/US20020086000A1/en
Priority to US09/965,395 priority patent/US20020081276A1/en
Priority to US09/977,479 priority patent/US20020086003A1/en
Priority to US09/976,712 priority patent/US20020086002A1/en
Priority to US09/977,074 priority patent/US20020136704A1/en
Priority to US09/976,598 priority patent/US20020110540A1/en
Priority to US09/976,599 priority patent/US20020086001A1/en
Priority to ZA200108451A priority patent/ZA200108451B/en
Priority to HK02107213.4A priority patent/HK1046249A1/en
Priority to US10/419,039 priority patent/US20040037816A1/en
Priority to US10/419,068 priority patent/US20050002913A1/en
Priority to US10/418,747 priority patent/US20040018180A1/en
Priority to US10/749,119 priority patent/US20040258672A1/en
Priority to US10/749,118 priority patent/US20040265285A1/en
Priority to US10/749,122 priority patent/US20040259803A1/en
Priority to US10/748,831 priority patent/US20050020524A1/en
Priority to US10/553,608 priority patent/US20070274946A1/en
Priority to US11/805,791 priority patent/US20080199495A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
AUPP9778A 1999-04-15 1999-04-15 Improvement of t cell mediated immunity Abandoned AUPP977899A0 (en)

Priority Applications (30)

Application Number Priority Date Filing Date Title
AUPP9778A AUPP977899A0 (en) 1999-04-15 1999-04-15 Improvement of t cell mediated immunity
CNB008089663A CN100376288C (en) 1999-04-15 2000-04-17 Improvement of T cell mediated immunity
JP2000611797A JP2002542174A (en) 1999-04-15 2000-04-17 Improvement of T cell mediated immunity
NZ514975A NZ514975A (en) 1999-04-15 2000-04-17 Improvement of T cell mediated immunity
BR0009712-8A BR0009712A (en) 1999-04-15 2000-04-17 Use of a sex steroid analog that disrupts the sex steroid that signals the thymus, and composition to increase an immune response to an antigen
KR1020017013148A KR20020007371A (en) 1999-04-15 2000-04-17 Improvement of t cell mediated immunity
EP00916705A EP1191975A4 (en) 1999-04-15 2000-04-17 Improvement of t cell mediated immunity
PCT/AU2000/000329 WO2000062657A2 (en) 1999-04-15 2000-04-17 Improvement of t cell mediated immunity
AU37977/00A AU779067B2 (en) 1999-04-15 2000-04-17 Improvement of T cell mediated immunity
CA002370296A CA2370296A1 (en) 1999-04-15 2000-04-17 Improvement of t cell mediated immunity
US09/966,575 US20020071829A1 (en) 1999-04-15 2001-09-26 Normalization of defective T cell responsiveness through manipulation of thymic regeneration
US09/966,576 US20020071833A1 (en) 1999-04-15 2001-09-26 Hematopoietic stem cell gene therapy
US09/965,394 US20020086000A1 (en) 1999-04-15 2001-09-26 Stimulation of thymus for vaccination development
US09/965,395 US20020081276A1 (en) 1999-04-15 2001-09-26 Disease prevention by reactivation of the thymus
US09/976,712 US20020086002A1 (en) 1999-04-15 2001-10-12 Hematopoietic stem cell gene therapy
US09/977,479 US20020086003A1 (en) 1999-04-15 2001-10-12 Stimulation of thymus for vaccination development
US09/976,599 US20020086001A1 (en) 1999-04-15 2001-10-12 Normalization of defective T cell responsiveness through manipulation of thymic regeneration
US09/977,074 US20020136704A1 (en) 1999-04-15 2001-10-12 Diagnostic indicator of thymic function
US09/976,598 US20020110540A1 (en) 1999-04-15 2001-10-12 Disease prevention by reactivation of the thymus
ZA200108451A ZA200108451B (en) 1999-04-15 2001-10-15 T-cell mediated immunity.
HK02107213.4A HK1046249A1 (en) 1999-04-15 2002-09-30 Improvement of t cell mediated immunity
US10/419,039 US20040037816A1 (en) 1999-04-15 2003-04-18 Graft acceptance through manipulation of thymic regeneration
US10/419,068 US20050002913A1 (en) 1999-04-15 2003-04-18 Hematopoietic stem cell gene therapy
US10/418,747 US20040018180A1 (en) 1999-04-15 2003-04-18 Stimulation of thymus for vaccination development
US10/749,119 US20040258672A1 (en) 1999-04-15 2003-12-30 Graft acceptance through manipulation of thymic regeneration
US10/748,831 US20050020524A1 (en) 1999-04-15 2003-12-30 Hematopoietic stem cell gene therapy
US10/749,118 US20040265285A1 (en) 1999-04-15 2003-12-30 Normalization of defective T cell responsiveness through manipulation of thymic regeneration
US10/749,122 US20040259803A1 (en) 1999-04-15 2003-12-30 Disease prevention by reactivation of the thymus
US10/553,608 US20070274946A1 (en) 1999-04-15 2004-04-19 Tolerance to Graft Prior to Thymic Reactivation
US11/805,791 US20080199495A1 (en) 1999-04-15 2007-05-24 Stimulation of thymus for vaccination development

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPP9778A AUPP977899A0 (en) 1999-04-15 1999-04-15 Improvement of t cell mediated immunity

Publications (1)

Publication Number Publication Date
AUPP977899A0 true AUPP977899A0 (en) 1999-05-13

Family

ID=3813977

Family Applications (2)

Application Number Title Priority Date Filing Date
AUPP9778A Abandoned AUPP977899A0 (en) 1999-04-15 1999-04-15 Improvement of t cell mediated immunity
AU37977/00A Ceased AU779067B2 (en) 1999-04-15 2000-04-17 Improvement of T cell mediated immunity

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU37977/00A Ceased AU779067B2 (en) 1999-04-15 2000-04-17 Improvement of T cell mediated immunity

Country Status (11)

Country Link
EP (1) EP1191975A4 (en)
JP (1) JP2002542174A (en)
KR (1) KR20020007371A (en)
CN (1) CN100376288C (en)
AU (2) AUPP977899A0 (en)
BR (1) BR0009712A (en)
CA (1) CA2370296A1 (en)
HK (1) HK1046249A1 (en)
NZ (1) NZ514975A (en)
WO (1) WO2000062657A2 (en)
ZA (1) ZA200108451B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040258672A1 (en) * 1999-04-15 2004-12-23 Monash University Graft acceptance through manipulation of thymic regeneration
US20020071829A1 (en) * 1999-04-15 2002-06-13 Richard Boyd Normalization of defective T cell responsiveness through manipulation of thymic regeneration
AUPR074500A0 (en) * 2000-10-13 2000-11-09 Monash University Treatment of t cell disorders
US20020086000A1 (en) * 1999-04-15 2002-07-04 Richard Boyd Stimulation of thymus for vaccination development
AU2002225245C1 (en) * 2000-10-13 2008-07-17 Norwood Immunology Ltd Improvement of graft acceptance through manipulation of thymic regeneration
AU1632002A (en) * 2000-10-13 2002-04-22 Richard Boyd Hematopoietic stem cell gene therapy
AU2002216320C1 (en) * 2000-10-13 2008-04-03 Norwood Immunology Ltd Hematopoietic stem cell gene therapy
AU2524502A (en) * 2000-10-13 2002-04-22 Richard Boyd Improvement of graft acceptance through manipulation of thymic regeneration
IL155412A0 (en) * 2000-10-13 2003-11-23 Univ Monash Diagnostic indicator of thymic function
AU2001295270B2 (en) * 2000-10-13 2007-08-09 Norwood Immunology Ltd Treatment of T cell disorders
IL155414A0 (en) * 2000-10-13 2003-11-23 Univ Monash Disease prevention by reactivation of the thymus
AU2002216323C1 (en) * 2000-10-13 2008-05-29 Norwood Immunology Ltd Disease prevention by reactivation of the thymus
IL147138A0 (en) * 2001-12-17 2002-08-14 Yeda Res & Dev Methods of and pharmaceutical compositions for modulating cell adhesion, migration and extravasation
JP2007518699A (en) * 2003-04-18 2007-07-12 ノーウッド・イミュノロジー・リミテッド Disease prevention and vaccination before thymus regeneration
CA2699012A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
CN103782173B (en) * 2011-07-01 2018-07-13 贝克曼考尔特公司 Regulatory T-cell and identification obtain and for treating based on immune disorderly method
CN103235135B (en) * 2013-04-26 2015-02-04 史其新 Detection method of characteristic cell mass for representing inhibitory activity of peripheral regulatory T cell, and application thereof
WO2019165197A1 (en) * 2018-02-23 2019-08-29 Duke University & Medical Center Cultured thymus tissue transplantation promotes donor-specific tolerance to allogeneic solid organ transplants
US11819520B2 (en) 2018-02-23 2023-11-21 Duke University Cultured thymus tissue transplantation promotes donor-specific tolerance to allogeneic solid organ transplants

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0282501A4 (en) * 1986-08-18 1989-11-14 Bunge Australia Regulating animal reproduction.
AU634379B2 (en) * 1991-04-29 1993-02-18 Csl Limited Recombinant immunocastration vaccine

Also Published As

Publication number Publication date
NZ514975A (en) 2004-03-26
CA2370296A1 (en) 2000-10-26
ZA200108451B (en) 2003-01-15
WO2000062657A3 (en) 2001-01-11
EP1191975A2 (en) 2002-04-03
CN1364093A (en) 2002-08-14
WO2000062657A2 (en) 2000-10-26
CN100376288C (en) 2008-03-26
AU779067B2 (en) 2005-01-06
AU3797700A (en) 2000-11-02
EP1191975A4 (en) 2005-05-25
BR0009712A (en) 2002-04-30
JP2002542174A (en) 2002-12-10
HK1046249A1 (en) 2003-01-03
KR20020007371A (en) 2002-01-26

Similar Documents

Publication Publication Date Title
AU3867400A (en) Methods of using bioelastomers
AU3706700A (en) Positively charged membrane
AUPP977899A0 (en) Improvement of t cell mediated immunity
AU7098000A (en) Signed group criteria
AU7653400A (en) Polyolefin production
AU1890300A (en) Novel interferon-alpha
AU5003600A (en) Charged membrane
AUPP938799A0 (en) Electrodes
AU4439700A (en) Insulator
AU2576100A (en) Novel enzyme
AU4587800A (en) Loudspeakers
AU4288900A (en) Production of polyethylene
AUPP924799A0 (en) Improved separator and process
AU5061000A (en) Novel glucoamylase
AU4582300A (en) Loudspeakers
AU6179400A (en) Multi-photodetector unit cell
AU4568900A (en) Improved can
AU2359301A (en) Novel ss-defensins
AUPQ120099A0 (en) Switch structure
AU7711800A (en) Novel uses of 2-bromopalmitate
AU3414700A (en) Centrifuge
AU4581500A (en) Loudspeakers
AU1581301A (en) Human chemokine beta-13
AU7279000A (en) Panel-shaped loudspeaker
AU4592500A (en) Switch

Legal Events

Date Code Title Description
NAA1 Application designating australia and claiming priority from australian document

Ref document number: 3797700

Country of ref document: AU